FDA Overview
The U.S. Food and Drug Administration (FDA) is responsible for regulating peptide drugs, ensuring safety and efficacy for approved medications, and overseeing compounding pharmacies. Understanding FDA regulations is crucial for anyone involved in peptide research or therapy.
Explore FDA Topics
Guidance Documents
Official FDA guidance on peptide drug development, quality standards, and manufacturing requirements.
Compounding Regulations
503A and 503B pharmacy rules, bulk drug substance lists, and compounding restrictions.
Warning Letters
FDA enforcement actions against peptide sellers, compounding pharmacies, and unapproved drug claims.
Drug Shortages
Current peptide drug shortages and their impact on compounding and patient access.
Key Regulatory Concepts
Drug Approval Process
Peptide drugs must go through the FDA's rigorous approval process:
- IND Application: Investigational New Drug application for clinical trials
- Phase 1-3 Trials: Safety and efficacy testing
- NDA/BLA: New Drug Application or Biologics License Application
- Post-Market Surveillance: Ongoing safety monitoring
Research Chemicals
Peptides sold as "research chemicals" occupy a complex regulatory space:
- Not FDA-approved for human use
- Cannot be marketed with health claims
- Legal to purchase for legitimate research
- FDA can take action if sold as drugs
Compounding
Compounding pharmacies can prepare peptide medications under specific conditions:
- 503A Pharmacies: Patient-specific prescriptions
- 503B Outsourcing Facilities: Larger scale, without prescriptions
- Bulk Drug List: Substances permitted for compounding
Recent FDA Actions
- 2024: Continued enforcement against semaglutide compounders
- 2023: Tirzepatide added to drug shortage list
- 2022: Updates to 503B outsourcing facility regulations